Recent Updates
Recently added Catalysts
IMNM Positive Sentiment

Immunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conference

Monday, November 2, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Immunome, a clinical-stage oncology company, announced its participation in the Guggenheim 3rd Annual Healthcare Innovation Conference. The presentation is scheduled for November 10, 2026, at 9 a.m. EST. Interested parties can access the live audio webcast via the company's website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Immunome is committed to developing targeted cancer therapies.
  • The company will present at a reputable healthcare conference.
  • The event provides a platform for investor engagement.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+27%
120-day peak, hindsight
Typical move
28.8%
average across 3 past catalysts
Cash runway
~23 mo
Low dilution risk
Lead asset
IM-1021
Phase 1 · Solid Malignancies

Full Press Release Details

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that its management will present at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026, at 9 a.m. EST. Interested parties can access the live audio webcast of the presentation from the Investor Relations section of the company’s website at www.immunome.com. The w

Frequently Asked Questions

When is Immunome's presentation at the conference?

The presentation is scheduled for November 10, 2026, at 9 a.m. EST.

Where can I access the presentation?

The live audio webcast can be accessed on Immunome's website.

What is the focus of Immunome's development?

Immunome focuses on developing targeted cancer therapies.

What type of company is Immunome?

Immunome is a clinical-stage targeted oncology company.

ShareAdd on Google
Tags: IMNM Immunome Guggenheim Conference healthcare innovation targeted oncology clinical-stage
Last updated: Nov 2, 2026

Biotech snapshot

Cash runway
$520M liquidity · $21M/mo burn
~23 mo
Low dilution risk
Lead asset
IM-1021Phase 1
Solid Malignancies →

Catalyst track record

+27%
best trade around IMNM's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for IMNM.

See every catalyst's timing & PoA →